阿替唑单抗
多西紫杉醇
无容量
医学
程序性细胞死亡1
化疗
肿瘤科
肺癌
PD-L1
内科学
癌症研究
免疫疗法
癌症
作者
Francesco Gelsomino,Alessandro Di Federico,Daria Maria Filippini,Filippo Gustavo Dall’Olio,Giuseppe Lamberti,Francesca Sperandi,Caterina Balacchi,Stefano Brocchi,Andrea Ardizzoni
标识
DOI:10.1016/j.cllc.2019.11.011
摘要
Immune checkpoint inhibitors (ICIs) have changed the clinical scenario in non–small-cell lung cancer (NSCLC). Nivolumab, an anti–programmed cell death 1 (PD-1) agent, has been demonstrated to be better than standard chemotherapy in pretreated squamous-cell lung cancers, showing a 2-fold higher response rate and a greater overall survival (OS) compared to docetaxel.1 Similarly, atezolizumab, an anti–programmed death ligand 1 (PD-L1) agent, showed a higher response rate and a longer OS compared to docetaxel.
科研通智能强力驱动
Strongly Powered by AbleSci AI